WebFeb 26, 2024 · one investigational medicine with two different dose groups. Masking: None (Open Label) Primary Purpose: Treatment. Official Title: Phase Ib/IIa Clinical Study of the … WebAug 27, 2024 · Bio-Thera is eligible for an upfront payment of $20 million as well as further development and commercial milestones of up to $130 million. “Partnering with Hikma to …
Bio-Thera Solutions, Ltd.,
WebSep 17, 2024 · Bio-Thera Solutions have signed an exclusive commercialization and licensing agreement with Hikma Pharmaceuticals for the ustekinumab (Stelara) biosimilar BAT2206, similar to an agreement reached between Meiji Seika Pharma, Dong-A ST and Intas Pharmaceuticals. WebOct 14, 2024 · Bio-Thera Solutions, Ltd., a leading global biotechnology company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune,... book mitford affair
Biogen and Bio-Thera Announce Positive Results From Phase 3 …
WebJun 1, 2024 · Bio-Thera Solutions, Ltd., a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel … WebDescription. Bio-Thera Solutions Ltd is engaged in research, development, and production of drugs and biosimilars. The company provides drug research and development; … WebAge : 64. Linked companies : Bio-Thera Solutions, Ltd. Summary. Jin Chen Yu is Executive Director & Deputy General Manager at Bio-Thera Solutions, Ltd. Current positions of Jin Chen Yu. Name. Title. Since. Bio-Thera Solutions, Ltd. book mixed cabin flights